Elevated Plasma Vascular Endothelial Cell Growth Factor and Thrombomodulin in Juvenile Diabetic Patients

Clinical and Applied Thrombosis/Hemostasis - Tập 5 Số 1 - Trang 21-24 - 1999
M. McLaren1, Tarik Elhadd1, Stephen Greene2, J. J. F. Belch1
1University Departments of Medicine
2Child Health, Ninewells Hospital and Medical School, Dundee DDI 9SY, Scotland, United Kingdom

Tóm tắt

The major cause of morbidity and mortality in pa tients with type 1 diabetes mellitus is vascular disease and the death rate in this group of patients can be up to six times that of the general population. Elevated levels of blood glucose can cause endothelial cell damage, and markers of endothelial dam age such as von Willebrand factor (vWF) and thrombomodulin (TM) have been reported to increase in adult diabetic patients. Growth factors are strongly linked to smooth muscle cell pro liferation that contributes significantly to the vascular occlusive process and it has been shown that vascular endothelial cell growth factor (VEGF) stimulates release of vWF from endo thelial cells. Vascular endothelial cell growth factor levels have been shown to be increased in vitreous fluid from the eyes of diabetic patients with proliferative retinopathy compared to those without. In this study we have shown that plasma levels of both TM and VEGF were significantly increased in juvenile diabetic patients with no clinical evidence of vascular disease compared to normal age and sex-matched control subjects. Me dian TM levels were 45.5 ng/mL (I.Q.R. 34 to 56 ng/mL) and 61 ng/mL (I.Q.R. 41 to 72 ng/mL) in the control group and in the diabetic patients respectively ( p = .0005) and median lev els of VEGF were 19.6 pg/mL (I.Q.R, 15.9 to 28.1 pg/mL) in the control group and 37.1 pg/mL (I.Q.R. 22.1 to 50.3 pg/mL) in the diabetic patients (p = .027 Mann-Whitney U test). This suggests that microvascular disease begins in childhood and can be detected using laboratory tests before any clinical changes are apparent. Key Words: Diabetes mellitus— Thrombomodulin—Vascular endothelial cell growth factor.

Từ khóa


Tài liệu tham khảo

Janka HU, 1980, Diabetes Care, 207, 13

10.1007/BF01228130

10.2337/diab.34.7.621

10.1093/rheumatology/30.6.433

Porta M. von, 1988, Diabet Med, 14, 523

10.1073/pnas.78.4.2249

10.1055/s-0038-1661034

10.1016/0049-3848(84)90120-8

10.1016/0009-8981(94)90036-1

10.1111/j.1464-5491.1995.tb00468.x

10.1002/(SICI)1098-2825(1996)10:3<119::AID-JCLA1>3.0.CO;2-6

10.1016/0168-8227(96)01283-1

Gabat S., 1996, J Vasc Dis, 25, 233

10.1210/edrv-13-1-18

10.1006/bbrc.1994.1240

10.1016/S0002-9394(14)75794-0

10.1159/000267567

10.1056/NEJM199309303291401

10.1111/j.1475-097X.1992.tb00306.x

10.1016/S0049-3848(96)00222-8

10.1016/0268-9499(90)90374-S

Thông tin
Thông tin xuất bản

Clinical and Applied Thrombosis/Hemostasis

Tập 5 Số 1

21-24

Thông tin tác giả